CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
多发性骨髓瘤患者的 CAR-T 细胞治疗：当前证据与挑战
英文原题：CAR T-Cell Therapy for Patients with Multiple Myeloma: Current Evidence and Challenges.
查看英文原题
CAR T-Cell Therapy for Patients with Multiple Myeloma: Current Evidence and Challenges.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
过去十年间，多发性骨髓瘤（MM）的治疗格局因新型疗法的涌现而受益。通过诱导T细胞杀伤靶癌细胞，嵌合抗原受体（CAR）T细胞疗法改善了血液系统恶性肿瘤患者的结局。B细胞成熟抗原（BCMA）是目前大多数正在研究用于MM的CAR-T 细胞产品的首选靶抗原。然而，其缺点涉及物流和临床挑战，包括可及性有限、生产时间和毒性。本文概述了近期开发和研究中的用于MM的CAR-T 细胞疗法，重点介绍当前证据和挑战。
展开英文摘要原文
The therapeutic landscape of multiple myeloma (MM) has benefited from an emergence of novel therapies over the last decade. By inducing T-cell kill of target cancer cells, chimeric antigen receptor (CAR) T-cell therapies have improved outcomes of patients with hematologic malignancies. B-cell maturation antigen (BCMA) is the current target antigen of choice for most CAR T-cell products under investigation for MM.
However, their shortcomings deal with logistical and clinical challenges, including limited availability, manufacturing times, and toxicities. This article provides an overview of recently developed and investigational CAR T-cell therapies for MM, highlighting current evidence and challenges.
论文信息
- 作者
- Rendo MJ、Joseph JJ、Phan LM、DeStefano CB
- 第一作者单位
- Department of Hematology/Oncology, Brooke Army Medical Center, San Antonio, TX, USA.United States
- 通讯作者单位
- Department of Hematology/Oncology, Walter Reed National Military Medical Center, Bethesda, MD, USA.United States
- 文献类型
- 综述
- 期刊
- Blood and lymphatic cancer : targets and therapy2022
- 原文标识
- PubMed 36060553 · DOI 10.2147/BLCTT.S327016
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →